Aytu Biopharma (AYTU) Operating Margin (2013 - 2026)
Aytu Biopharma's (AYTU) quarterly Operating Margin came in at 32.75% in Q1 2026, down 4587.0% year-on-year from 0.73% in Q1 2025, and down 152.07% on a QoQ basis from 12.99% in Q4 2025.
Aytu Biopharma (AYTU) Operating Margin (2013 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 14 years of Operating Margin data on file, last reported at 32.75% in Q1 2026.
- On a quarterly basis, Operating Margin fell 4587.0% year-over-year to 32.75% in Q1 2026; TTM through Mar 2026 was 26.79%, a 2302.0% decrease from a year earlier, with the FY2025 full-year figure at 11.79%, down 935.0% from the prior year.
- Operating Margin for Q1 2026 stood at 32.75%, down from 12.99% in the prior quarter.
- Over the last five years, Operating Margin for AYTU reached as high as 16.78% in Q4 2023 and fell as low as 220.76% in Q1 2022.
- Historically, Operating Margin has averaged 28.07% across 5 years, with a median of 11.39% in 2024.
- Across the five-year window, Operating Margin jumped 18311 bps in 2023 and plunged 4587 bps in 2026, its largest moves.
- Year by year, Operating Margin stood at 26.13% in 2022, then jumped by 164 bps to 16.78% in 2023, then sank by 162 bps to 10.45% in 2024, then fell by 24 bps to 12.99% in 2025, then plunged by 152 bps to 32.75% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 32.75% in Q1 2026, 12.99% in Q4 2025, and 10.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Aytu Biopharma | 1.43 Mn | -25.28 Mn | 7.60 Mn | -32.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.75% |
| Dec 31, 2025 | -12.99% |
| Sep 30, 2025 | -10.83% |
| Jun 30, 2025 | -50.37% |
| Mar 31, 2025 | 13.12% |
| Dec 31, 2024 | -10.45% |
| Sep 30, 2024 | -5.61% |
| Jun 30, 2024 | -15.58% |
| Mar 31, 2024 | -11.39% |
| Dec 31, 2023 | 16.78% |
| Sep 30, 2023 | -4.87% |
| Jun 30, 2023 | 0.55% |
| Mar 31, 2023 | -37.65% |
| Dec 31, 2022 | -26.13% |
| Sep 30, 2022 | -6.54% |
| Jun 30, 2022 | -61.72% |
| Mar 31, 2022 | -220.76% |
| Dec 31, 2021 | -48.84% |
| Sep 30, 2021 | -126.50% |
| Jun 30, 2021 | -102.51% |